This is a working overview of mitochondrial biogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
==== Member of the Order of the British Empire (MBE) ==== Civil Daniel Ogu Besa's. For services to Agricultural Development and to the Community. Christopher Bwekulyi. For services to the Correctional Service and to the Community. Anthony Pisupisu. For services to Justice and to the Community
== Complications == LA-ICP-MS function optimally with gold particles greater than 60 μm in diameter to avoid any contamination during measurements. Although LA-ICP-MS has a lower detection limit, its overall precision was lower than other analysis techniques for trace element concentrations such as field emission-electron probe microanalysis (FE-EPMA) and synchrotron micro X-ray fluorescence spectroscopy (SR-l-XRF). Due to the small size of gold (<5μm-250μm) small fragments of minerals need to be separated from the gold before analysis can occur. Gold fingerprinting has limitations including elemental fractionation (the non-sample related analyte) and calibration requires matrix-matched standards. A few other problems exist that limit actual sourcing or provencancing of gold in relation to manufactured art objects. These problems include: a lack of an extensive database of elemental profiles in gold ores, the natural differences that coexist in ore geology and the difficulties of accurately analyzing trace elements. Also, trading, looting and re-melting of so called “precious” metal objects add to the problem of sourcing.
In 2021, following Nature's 2019 publication of anomalous findings that might only be explained by some localized fusion, scientists at the Naval Surface Warfare Center, Indian Head Division announced that they had assembled a group of scientists from the Navy, Army and National Institute of Standards and Technology to undertake a new, coordinated study. With few exceptions, researchers have had difficulty publishing in mainstream journals. The remaining researchers often term their field Low Energy Nuclear Reactions (LENR), Chemically Assisted Nuclear Reactions (CANR), Lattice Assisted Nuclear Reactions (LANR), Condensed Matter Nuclear Science (CMNS) or Lattice Enabled Nuclear Reactions; one of the reasons being to avoid the negative connotations associated with "cold fusion". The new names avoid making bold implications, like implying that fusion is actually occurring. The researchers who continue their investigations acknowledge that the flaws in the original announcement are the main cause of the subject's marginalization, and they complain of a chronic lack of funding and no possibilities of getting their work published in the highest impact journals. University researchers are often unwilling to investigate cold fusion because they would be ridiculed by their colleagues and their professional careers would be at risk. In 1994, David Goodstein, a professor of physics at Caltech, advocated increased attention from mainstream researchers and described cold fusion as:
Darbar ( transl. Court) is a 2020 Indian Tamil-language action thriller film written and directed by AR Murugadoss, and produced by Allirajah Subaskaran under the banner Lyca Productions. The film stars Rajinikanth, Suniel Shetty, Nayanthara and Nivetha Thomas. It follows Aaditya Arunasalam (Rajinikanth), the commissioner of Mumbai Police, who sets out to curb the city's rampant drug-trafficking and prostitution. When he uncovers a deep controversy linked to an international drug lord, however, he tries to fulfill his secret agenda. The film is Rajinikanth's first role as a police officer in 27 years following Pandiyan (1992). The project's working title was Thalaivar 167 and the title Darbar was officially announced on 9 April 2019. Principal photography commenced the same month, mostly in Mumbai, and was completed in October 2019. Anirudh Ravichander composed the music for the film. The cinematographer was Santosh Sivan and the editor was A. Sreekar Prasad. Darbar was released theatrically in India on 9 January 2020, coinciding with the Pongal festival. The film met with mixed reviews upon release with praise for Rajinikanth’s performance and grossed ₹250 crore at the box office, making it the highest-grossing Tamil film of 2020 and 4th highest-grossing Indian film of 2020. Darbar became Rajinikanth’s fifth film to gross over ₹200 crore worldwide, following Enthiran, Kabali, 2.0, and Petta.
== Diagnosis == Reticulocytosis is typically diagnosed through a reticulocyte count, which measures the percentage or absolute number of reticulocytes in the blood. Common diagnostic tools for hematological disorders that may cause reticulocytosis include: Reticulocyte Production Index (RPI): Calculation that corrects for reticulocytes counts that may be misleadingly elevated due to the decrease in total red blood cells seen in anemia. Calculated as [%reticulocyte count x Patient Hct] / 45(normal Hct). This adjustment provides insight into whether reticulocyte production is adequate for the level of anemia. Complete Blood Count (CBC): Provides a value for a variety of blood components, including red blood cells, hemoglobin, and hematocrit levels. Peripheral Blood Smear: Common lab test in the work up of blood disorders that evaluates the size, shape, and maturity of red blood cells and reticulocytes by observing them under a microscope. This can help narrow down the etiology of the reticulocytosis.
Sources: en.wikipedia.org
== External links == IFR/JIC TOF MS Tutorial Jordan TOF Products TOF Mass Spectrometer Tutorial University of Bristol TOF-MS Tutorial Kore Technology – Introduction to Time-of-Flight Mass Spectrometry
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients. Both elbasvir and grazoprevir were developed by Merck & Co. The US Food and Drug Administration (FDA) approved the drug in January 2016.
The pineal gland is located in the diencephalon of the brain. It primarily releases melatonin, which influences daily rhythms and may have an antigonadotropic effect in humans. It may also influence the melanotropes and melanocytes located in the skin.
There are three types of myomeres observed in fish-like chordates: amphioxine (lancelet), cyclostomine (jawless fish), and gnathostomine (jawed fish). All myomeres flex the body laterally into concavity to provide force for locomotion. Since myomeres are composed of multinucleated myofibers (contractile cells), force can be generated via muscle contraction that gets transmitted by the intricate connective tissue (myosepta) network. Myomeres compose most of the lateral musculature and provide propulsive force to travel along the line of travel. In this sense, they cause flexion to either side in order to produce locomotor force (the forward swimming motion). Myomeres attach to centra of vertebrae, and neural and haemal spines. The folded shape of each myomere as V- or W-shaped extends over various axial segments, allowing fibers control over a large amount of the body. There are different variations of myomere activation depending on the type of swimming or movement. For example, high loading situations such as fast-starts and turning require almost maximal myomere activation in teleost fish. Further, if swim speeds are lower and movement is in one plane, there is less activation of myomeres. Research has discovered that fish are able to spatially restrict axial myomeres during different swimming behaviors.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.